Inventage Lab

Inventage Lab Financial Debt Ratio

The Financial Debt Ratio of Inventage Lab (389470.KQ) as of Oct 22, 2026 is 2.12 %. In the previous year, Financial Debt Ratio was 22.56 % — a change of -90.62% (lower).

Financial Debt Ratio

2.12 %

YoY

-90.62%

Last updated:

Financial Debt Ratio of Inventage Lab is 2025 2.12 % . Financial Debt Ratio of Inventage Lab was 2024 22.56 % . It decreases by -90.62% lower compared to the previous year.

The Inventage Lab Financial Debt Ratio history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Financial Debt Ratio
Date
Financial Debt Ratio
Jan 1, 2019
35.25 KRW
Jan 1, 2020
21.64 KRW
Jan 1, 2021
12.52 KRW
Jan 1, 2022
8.03 KRW
Jan 1, 2023
23.71 KRW
Jan 1, 2024
22.56 KRW
Jan 1, 2025
2.12 KRW
The Inventage Lab Financial Debt Ratio history
YEARFinancial Debt RatioYoY
2.12 %-90.62%
22.56 %-4.87%
23.71 %+195.22%
8.03 %-35.84%
12.52 %-42.14%
21.64 %-38.61%
35.25 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Inventage Lab Stock analysis

What does Inventage Lab do? Inventage Lab, Inc. generates revenue through the research, manufacture, and sale of human medicines targeting male pattern baldness, dementia, and prostate cancer, as well as veterinary medicines including combination drugs and chemical castration agents. The company leverages its proprietary platforms for long-acting injections and genetic material drug delivery to develop and scale production of these products. Its human medicine segment focuses on therapeutic areas with significant market demand, while veterinary medicines serve agricultural and companion animal markets. The firm's business model centers on proprietary technology platforms applied to both human and veterinary pharmaceutical development. These platforms enable the company to create and mass-produce innovative drug delivery systems, which are critical for the efficacy of their medicine portfolios. Revenue streams are derived from direct sales of these medicines to healthcare providers and veterinary institutions within their target markets. Inventage Lab, Inc. operates with a dual focus on human and veterinary pharmaceuticals, utilizing its specialized platforms to address unmet medical needs in both sectors. The company's product range includes treatments for specific conditions like male pattern baldness and prostate cancer, alongside veterinary applications such as chemical castration agents, which are sold to relevant industry stakeholders in their respective markets. Inventage Lab is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Inventage Lab stock

Financial Debt Ratio of Inventage Lab is 2.12 % in 2025.

Financial Debt Ratio of Inventage Lab changed from 22.56 % to 2.12 %, representing a -90.62% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Financial Debt Ratio Inventage Lab since 2006 – with annual values, charts, and detailed analysis.

The financial debt ratio measures interest-bearing financial debt as a percentage of total assets. It isolates funded debt from trade and other non-financial obligations.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Financial Debt Ratio's Inventage Lab with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Inventage Lab

All Key Metrics — Inventage Lab